Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 37 analyst ratings
Buy
Strong Buy 41%
Buy 46%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Danaher has undergone a strategic transformation from a real estate organization to a focused industrial manufacturer, particularly within the life science and diagnostic sectors. Recent trends indicate a resurgence in biotech approvals and steady growth in gene and cell therapy activities, which are expected to positively influence Danaher's commercial operations, especially within its Cytiva business that benefits from on-market products. With strong sequential order growth observed in the biotech segment and a projected EPS acceleration towards $9 by FY26, financial indicators suggest a favorable outlook for Danaher's future performance.

Bears say

Danaher's financial outlook appears negative due to several key factors impacting its revenue projections and market environment. The company's FY'25 revenue guidance of +3% organic growth falls approximately 200 basis points short of analysts' expectations, primarily driven by a projected $300 million decline in respiratory sales and $100 million in pricing challenges within the China diagnostics business. Moreover, external risks, including the potential impact of U.S. and international regulatory changes, decreased spending in biopharmaceuticals, and uncertainty surrounding academic funding, further compound the outlook for Danaher's financial performance.

Danaher (DHR) has been analyzed by 37 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 46% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 37 analysts, Danaher (DHR) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.